Media Pack
News

Current Edition

Volume 16 Issue 2
 
news

OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy

OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug ...
24 January 2018 news application | cancer
Continue Reading →
news

BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors as a potential cornerstone of combination ca...
10 January 2018 news cancer | combination therapy
Continue Reading →
news

Pegfilgrastim Biosimilar Matches Reference Product

Sandoz's biosimilar of Neulasta, or pegfilgrastim, matched the reference product in a clinical trial, according to the company. Researchers found equivalence in pharm...
20 December 2017 news biosimilar | cancer
Continue Reading →
news

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment o...
13 December 2017 news antibody | autoimmune
Continue Reading →
news

JW Pharma releases cancer treatment trial results

South Korea based JW Pharmaceuticals recently presented phase 1a/1b clinical trial results for CWP291, a target anticancer treatment that uses Wnt signaling pathway, ...
13 December 2017 news cancer | result
Continue Reading →
news

GamaMabs Pharma sees two peer-reviewed articles published in Oncotarget, detailing the anti-tumor activity of GM102/3C23K

GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting AMHR2 for the treatment of cancer, today announces that two peer-review...
6 December 2017 news antibodies | cancer
Continue Reading →
news

Cristal Therapeutics Awarded €2.5 Million Horizon 2020 Grant to Advance Its CriPec®-docetaxel Through Phase 2 Trials

 Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet pat...
29 November 2017 news cancer | grant
Continue Reading →
news

SOTIO Broadens Its Phase II Clinical Trial Program in Ovarian Cancer

SOTIO, a biotechnology company owned by the PPF Group, today announced the enrollment of the first patient to a Phase II study testing DCVAC/OvCa in combination with ...
29 November 2017 news cancer | chemotherapy
Continue Reading →
news

New study results support use of DiviTum ® for evaluation of pancreatic cancer

In collaboration with University of Heidelberg, Germany, results from a clinical study of pancreatic cancer are published in the Pancreas scientific journal. The res...
22 November 2017 news cancer | clinical
Continue Reading →
news

Arcus Biosciences secures funding to advance clinical programs for AB928

Clinical-stage biotechnology company Arcus Biosciences has completed a $107m series C financing, bringing the total equity capital to around $227m. The proceeds from ...
22 November 2017 news biotechnology | cancer
Continue Reading →
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte